GW Pharmaceuticals PLC- (NASDAQ:GWPH) Position Trimmed by Eqis Capital Management Inc.

Eqis Capital Management Inc. trimmed its holdings in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 3.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,874 shares of the biopharmaceutical company’s stock after selling 236 shares during the period. Eqis Capital Management Inc.’s holdings in GW Pharmaceuticals PLC- were worth $1,013,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. Federated Investors Inc. PA boosted its position in GW Pharmaceuticals PLC- by 23.5% during the 1st quarter. Federated Investors Inc. PA now owns 417,750 shares of the biopharmaceutical company’s stock worth $70,420,000 after purchasing an additional 79,367 shares during the period. Victory Capital Management Inc. boosted its position in GW Pharmaceuticals PLC- by 80.4% during the 1st quarter. Victory Capital Management Inc. now owns 408,940 shares of the biopharmaceutical company’s stock worth $68,935,000 after purchasing an additional 182,210 shares during the period. Marshall Wace North America L.P. boosted its position in GW Pharmaceuticals PLC- by 1,564.3% during the 1st quarter. Marshall Wace North America L.P. now owns 316,899 shares of the biopharmaceutical company’s stock worth $53,419,000 after purchasing an additional 297,858 shares during the period. Deutsche Bank AG boosted its position in GW Pharmaceuticals PLC- by 18.2% during the 4th quarter. Deutsche Bank AG now owns 270,575 shares of the biopharmaceutical company’s stock worth $26,350,000 after purchasing an additional 41,593 shares during the period. Finally, Millennium Management LLC purchased a new stake in GW Pharmaceuticals PLC- during the 4th quarter worth $15,685,000. 78.92% of the stock is owned by hedge funds and other institutional investors.

GWPH has been the subject of a number of analyst reports. BidaskClub cut shares of GW Pharmaceuticals PLC- from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 24th. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $192.00 price objective for the company in a research report on Monday. ValuEngine cut shares of GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research report on Monday. Oppenheimer upped their price objective on shares of GW Pharmaceuticals PLC- from $234.00 to $239.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, CIBC raised shares of GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $212.70.

In related news, insider Volker Knappertz sold 12,144 shares of the stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $14.64, for a total transaction of $177,788.16. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director William A. Waldegrave sold 3,576 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $15.00, for a total transaction of $53,640.00. Following the sale, the director now owns 3,576 shares in the company, valued at approximately $53,640. The disclosure for this sale can be found here. In the last 90 days, insiders sold 378,288 shares of company stock worth $5,710,525. Company insiders own 3.60% of the company’s stock.

Shares of GW Pharmaceuticals PLC- stock opened at $152.92 on Friday. The firm has a market cap of $4.82 billion, a PE ratio of -14.48 and a beta of 2.25. The firm’s 50-day simple moving average is $166.13 and its 200-day simple moving average is $166.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.59 and a current ratio of 8.31. GW Pharmaceuticals PLC- has a 1 year low of $90.14 and a 1 year high of $196.00.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.96. The business had revenue of $72.04 million for the quarter, compared to analyst estimates of $37.28 million. GW Pharmaceuticals PLC- had a negative net margin of 101.45% and a negative return on equity of 38.09%. The company’s revenue for the quarter was up 2096.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.25) EPS. On average, equities analysts predict that GW Pharmaceuticals PLC- will post -3.84 earnings per share for the current year.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Recommended Story: What is a put option?

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.